Review





Similar Products

ihc staining protocol  (Betta Pharmaceuticals Co Ltd)
90
Betta Pharmaceuticals Co Ltd ihc staining protocol
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Ihc Staining Protocol, supplied by Betta Pharmaceuticals Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pmc12006399-146-15-44?v=Betta+Pharmaceuticals+Co+Ltd
Average 90 stars, based on 1 article reviews
ihc staining protocol - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ihc staining positive determination protocol  (Betta Pharmaceuticals Co Ltd)
90
Betta Pharmaceuticals Co Ltd ihc staining positive determination protocol
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Ihc Staining Positive Determination Protocol, supplied by Betta Pharmaceuticals Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pmc12006399-146-34-44?v=Betta+Pharmaceuticals+Co+Ltd
Average 90 stars, based on 1 article reviews
ihc staining positive determination protocol - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dab ihc protocol  (OptiView Technologies)
90
OptiView Technologies dab ihc protocol
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Dab Ihc Protocol, supplied by OptiView Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm39617889-445-13-3?v=OptiView+Technologies
Average 90 stars, based on 1 article reviews
dab ihc protocol - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ihc-p protocol pv-9004  (ZSGB Biotech)
90
ZSGB Biotech ihc-p protocol pv-9004
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Ihc P Protocol Pv 9004, supplied by ZSGB Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm39469784-218-8-10?v=ZSGB+Biotech
Average 90 stars, based on 1 article reviews
ihc-p protocol pv-9004 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ihc select hrp/dab protocol  (Merck KGaA)
90
Merck KGaA ihc select hrp/dab protocol
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Ihc Select Hrp/Dab Protocol, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm39462866-109-14-17?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
ihc select hrp/dab protocol - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
chromogenic ihc staining of formalinfixed paraffin embedded (ffpe) tissue protocol  (Novus Biologicals)
90
Novus Biologicals chromogenic ihc staining of formalinfixed paraffin embedded (ffpe) tissue protocol
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Chromogenic Ihc Staining Of Formalinfixed Paraffin Embedded (Ffpe) Tissue Protocol, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm38896196-541-8-0?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
chromogenic ihc staining of formalinfixed paraffin embedded (ffpe) tissue protocol - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
amyloid precursor protein antibody staining protocol for ihc  (Novocastra)
90
Novocastra amyloid precursor protein antibody staining protocol for ihc
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Amyloid Precursor Protein Antibody Staining Protocol For Ihc, supplied by Novocastra, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/10__2478_slash_macvetrev___2024___0018-73-26-30?v=Novocastra
Average 90 stars, based on 1 article reviews
amyloid precursor protein antibody staining protocol for ihc - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ihc analysis protocol packages (app) algorithm  (Visiopharm AS)
90
Visiopharm AS ihc analysis protocol packages (app) algorithm
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Ihc Analysis Protocol Packages (App) Algorithm, supplied by Visiopharm AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pmc11065694__41590_2024_1802_MOESM2_ESM-186-24-2?v=Visiopharm+AS
Average 90 stars, based on 1 article reviews
ihc analysis protocol packages (app) algorithm - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
pd-l1 ihc staining protocols  (Bydgoszcz)
90
Bydgoszcz pd-l1 ihc staining protocols
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Pd L1 Ihc Staining Protocols, supplied by Bydgoszcz, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm37804360-26-64-61?v=Bydgoszcz
Average 90 stars, based on 1 article reviews
pd-l1 ihc staining protocols - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
protocol for ihc  (College of American Pathologists)
90
College of American Pathologists protocol for ihc
Identification of patients <t>with</t> <t>RDAA</t> NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b <t>IHC</t> staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)
Protocol For Ihc, supplied by College of American Pathologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+protocol/pm37077064-61-13-6?v=College+of+American+Pathologists
Average 90 stars, based on 1 article reviews
protocol for ihc - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Identification of patients with RDAA NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b IHC staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)

Journal: Signal Transduction and Targeted Therapy

Article Title: RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

doi: 10.1038/s41392-025-02206-x

Figure Lengend Snippet: Identification of patients with RDAA NSCLC. a Quantification of plasma RNase1 in NSCLC patients (N = 48) and normal individuals (N = 15). RNase1 concentration was measured by ELISA as described in Methods. p < 0.01, Student’s t -test. b IHC staining of RNase1 in human lung tumors (N = 48) and normal lung (N = 10) tissues. RNase1 expression level was calculated based on the intensity and percentage of stained cells as described in Methods. Representative images shown. c Correlation analysis between plasma RNase1 concentration and RNase1 expression level in paired tumor tissues (N = 47). R = 0.84, Pearson’s Chi-Square test. d IHC staining of RNase1 expression and ALK phosphorylation levels in human NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 specific antibodies were used for IHC staining. Representative images shown. e Diagnosis of RDAA NSCLC patients in 1173 NSCLC tissues. ALK p-Y1604, ALK p-Y1282/1283 and RNase1 were used as biomarkers to identify RDAA positive samples. f Correlation analysis between RNase1 expression and ALK phosphorylation in NSCLC tissues which used from ( e ). ALK p-Y1604 and 1282/1283 double positive means ALK phosphorylation positive (pALK + ), otherwise means ALK phosphorylation negative (pALK-)

Article Snippet: Based on previous experimental results, we defined the tumor as RDAA positive only when the IHC staining results of the above three antibodies were triple-positive (Fig. , the antibodies of RDAA, the protocol for immunohistochemical staining and positive determination of RDAA were supported by Betta Pharmaceuticals Co., Ltd, more details see Methods).

Techniques: Clinical Proteomics, Concentration Assay, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Expressing, Staining, Phospho-proteomics, Biomarker Discovery